OpGen

The firm said it expects FDA clearance for its Acuitas AMR Gene Panel, although it has been delayed due to the agency's extended review timelines.

OpGen will promote the system for the enrichment of circulating endothelial cells from whole blood, which could be useful for COVID-19 research.

The additional €5 million from the European Investment Bank will co-fund R&D across the platforms and product portfolios of Curetis and Ares Genetics.

The first year's pilot phase aimed to develop an infectious disease digital health and precision medicine platform connecting healthcare facilities to NYSDOH.

The firm recently announced a collaboration with Sweden’s Karolinska Institute to test COVID-19 pneumonia patients for bacterial co-infections.

The institute will use Curetis' Unyvero Hospitalized Pneumonia panel on high-risk patients admitted to the ICU for COVID-19 pneumonia.

The company's revenue was largely attributed to its Acuitas AMR Gene Panel and Acuitas Lighthouse informatics platform.

OpGen also reported full-year growth was driven by revenue increases for its Acuitas AMR Gene Panel and Acuitas Lighthouse informatics platform.

OpGen, which is acquiring Curetis, said that combined revenue for both companies would have been about $6 million in 2019 had the deal been completed last year.

The company also inked a deal with an investment bank to publicly offer from time to time up to $4.2 million of its stock.